UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	 FIRST NAMED INVENTOR 	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/617,038	07/11/2003	Peter Andersen	SSI5AUSA	5215
	7590 10/30/2007		EXAMINER ·	
HOWSON AND HOWSON SUITE 210 501 OFFICE CENTER DRIVE FT WASHINGTON, PA 19034			SWARTZ, RODNEY P	
			ART UNIT	PAPER NUMBER
TT WASHINGTON,TA 1205			1645	
			MAIL DATE	DELIVERY MODE
			10/30/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<u> </u>	Application No.	Applicant(s)				
	10/617,038	ANDERSEN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Rodney P. Swartz, Ph.D.	1645				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period way reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 10 Au						
, 	·					
, —	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
closed in accordance with the practice under E	х рапе Quayle, 1935 С.D. 11, 45	03 U.G. 213.				
Disposition of Claims						
4) Claim(s) 6-10,12,13,16,17 and 23-27 is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) 9,10,12,13,16,17 is/are allowed.						
6) Claim(s) 6-8 and 23-27 is/are rejected.						
7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or	r election requirement					
o/are subject to restriction and/or	ciccion requirement.					
Application Papers						
9)☐ The specification is objected to by the Examine	r.					
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
The dath of declaration is objected to by the Ex	arminer. Note the attached Office	Action of form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
·						
Attachment(s)						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application						
Paper No(s)/Mail Date 6) Other:						

Application/Control Number: 10/617,038

Art Unit: 1645

DETAILED ACTION

- 1. Applicants' Response to Office Action, received 10 August 2007, is acknowledged. Claim 6 has been amended. New claims 23-27 have been added.
- 2. Claims 6-10, 12, 13, 16, 17, and 23-27 are pending and under consideration.

Rejections Withdrawn

- 3. The rejection of claims 6-8 under 35 U.S.C. 102(b) as being anticipated by Eisenberg et al (WO01/35317, 17May2001) is withdrawn in light of the amendment of the claims.
- 4. The objection to claims 9, 10, 12, 13, 16, and 17 is withdrawn.

Claim Rejections - 35 USC § 112

- 5. The following is a quotation of the second paragraph of 35 U.S.C. 112:
 - The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 6. Claims 6-8, 23-25 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Newly amended claim 6 now recites that the vaccine comprises a pharmaceutically acceptable "polymeric" carrier. There is no recitation that the polypeptides or fragments thereof be attached to the carrier. However, page 48, lines 23-28, specifically recite that when polymeric carriers are utilized, these "Suitable carriers are selected from the group consisting of a polymer to which the polypeptide(s) is/are bound by hydrophobic non-covalent interaction, such as a plastic, e.g. polystyrene, or a polymer to which the polypeptide(s) is/are covalently bound, such as a polysaccharide, or a polypeptide, e.g. bovine serum albumin, ovalbumin or keyhole limpet haemocyanin."

Application/Control Number: 10/617,038

Art Unit: 1645

Thus, it is unclear in claims, if the claimed vaccines have the polypeptides/fragments bound to the carrier, and what type of binding, i.e., hydrophobic non-convalent interaction, or covalently interaction.

Conclusion

- 7. Claims 6-8 and 23-27 are rejected. Claims 9, 10, 12, 13, 16, and 17 appear to be allowable.
- 8. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

9. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rodney P. Swartz, Ph.D., Art Unit 1645, whose telephone number is (571) 272-0865. The examiner can normally be reached on Monday through Thursday from 9:00 AM to 7:30 PM EST.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's acting Supervisor, Bruce Campell, can be reached on (571)272-0974.

Application/Control Number: 10/617,038 Page 4

Art Unit: 1645

The fax phone number for the organization where this application or proceeding is

assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private

PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

RODNEY P SWARTZ, PH.D PRIMARY EXAMINER

Art Unit 1645

October 23, 2007